Ascendis Pharma A/S - ADR (ASND)

Historical Holders from Q1 2015 to Q3 2025

Symbol
ASND on Nasdaq
CUSIP
04351P101
Type / Class
Equity / ADR
Shares outstanding
55.6M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
63.8M
Holdings value
$12.7B
% of all portfolios
0.023%
Grand Portfolio weight change
+0%
Number of holders
272
Number of buys
151
Number of sells
-113
Average Value change %
0%
Average buys %
+0.005%
Average sells %
-0.006%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Ascendis Pharma A/S - ADR (ASND)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WESTFIELD CAPITAL MANAGEMENT CO LP 9.18% $789M 5.53M Westfield Capital Management Company, L.P. Dec 31, 2024
FMR LLC 8% $663M 4.65M FMR LLC Mar 31, 2025
JANUS HENDERSON GROUP PLC 7.8% -2.5% $859M -$20.8M 4.32M -2.37% JANUS HENDERSON GROUP PLC Sep 30, 2025
Capital International Investors 5.6% $611M 3.11M Capital International Investors Jun 30, 2025
T. Rowe Price Investment Management, Inc. 4.8% -26.7% $530M -$182M 2.67M -25.6% T. Rowe Price Investment Management, Inc. Sep 30, 2025

Institutional Holders of Ascendis Pharma A/S - ADR (ASND)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 63.8M $12.7B +$232M $198.81 272
2025 Q2 62.9M $10.9B -$374M $172.60 245
2025 Q1 65.2M $10.1B +$223M $155.86 240
2024 Q4 63.7M $8.78B +$116M $137.67 211
2024 Q3 62.6M $9.31B +$237M $149.31 219
2024 Q2 60.6M $8.26B -$25.1M $136.38 201
2024 Q1 60.8M $9.19B +$195M $151.17 189
2023 Q4 113K $14.3M +$9.81M $125.95 4
2023 Q3 60.3M $5.64B -$73.7M $93.64 155
2023 Q2 61M $5.44B -$43.6M $89.25 153
2023 Q1 61M $6.53B -$599M $107.22 158
2022 Q4 65.9M $8.05B -$71.1M $122.13 179
2022 Q3 66.6M $6.88B +$156M $103.26 172
2022 Q2 63.2M $5.87B +$102M $92.96 160
2022 Q1 61.9M $7.27B +$414M $117.36 167
2021 Q4 58.4M $7.85B -$60.4M $134.53 166
2021 Q3 58M $9.24B +$506M $159.39 163
2021 Q2 55M $7.24B +$272M $131.55 170
2021 Q1 52.7M $6.79B -$267M $128.88 171
2020 Q4 54.1M $9.02B +$127M $166.78 169
2020 Q3 53.3M $8.23B +$764M $154.32 148
2020 Q2 48.2M $7.13B +$38.8M $147.90 149
2020 Q1 47.9M $5.39B +$191M $112.61 142
2019 Q4 46.1M $6.42B -$13.1M $139.12 138
2019 Q3 46.1M $4.44B -$194M $96.32 126
2019 Q2 47.7M $5.49B +$238M $115.15 132
2019 Q1 46M $5.41B +$712M $117.70 137
2018 Q4 40.1M $2.51B -$10.8M $62.65 102
2018 Q3 40.2M $2.85B +$44.5M $70.86 94
2018 Q2 39.6M $2.63B +$96.2M $66.52 99
2018 Q1 38.1M $2.49B +$345M $65.40 89
2017 Q4 30.5M $1.22B +$52.9M $40.06 64
2017 Q3 28.8M $1.04B +$201M $36.25 59
2017 Q2 23.3M $646M +$76.1M $27.76 34
2017 Q1 20.9M $585M +$9.05M $28.00 34
2016 Q4 20.6M $416M +$131M $20.24 30
2016 Q3 14M $281M +$4.79M $20.10 22
2016 Q2 13.9M $184M +$10.2M $13.27 23
2016 Q1 12M $223M +$9.84M $18.55 25
2015 Q4 10.1M $185M +$3.82M $18.32 24
2015 Q3 7.46M $132M +$7.98M $17.70 23
2015 Q2 8.95M $158M -$8M $17.68 31
2015 Q1 7.45M $128M +$128M $17.35 34